Hutchmed China Ltd (Hutchmed) discovers, develops, and commercializes targeted therapies for cancer and immunological diseases. The company manufactures pharmaceuticals and health-related consumer products and sells them in China and Hong Kong. It develops and advances a pipeline portfolio of novel oral drug candidates for cancer and inflammation in China, North America, Europe, and Australia. Hutchmed manufactures commercial platform products at its facilities in Shanghai, Guangzhou, and Bozhou in China.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Hutchmed is dedicated to developing innovative treatments for cancer and immune-related diseases. Its approach combines targeted therapies, immunotherapies, and other therapeutic pathways. The company is progressing both small-molecule and biologic programs designed to address abnormal genetic drivers, influence the tumor immune microenvironment, and inhibit immune checkpoint targets. Hutchmed’s goal is to deliver differentiated oncology and immunology therapies with global potential, supported by its in-house discovery capabilities and collaborations with leading pharmaceutical partners. Its end-to-end R&D organization covers key functions including chemistry, biology, pharmacology, toxicology, manufacturing and controls for clinical and commercial supply, clinical development, and regulatory affairs. The company’s R&D hubs are based in Shanghai, China, with international clinical operations located in New Jersey, USA. In FY2025, the company spent US$148.3 million on its R&D activities, which as a percentage of revenue stood at 27% and declined 30% YoY. The company has more than ten clinical-stage investigational drug candid¬ates with several more in preclinical testing. These drug candidates target both novel and validated pathways, including MET, VEGFR, FGFR, CSF-1R, PI3Kd, Syk, IDH, ERK, EGFR, BTK, and CD47, among others. Some of its pipeline drugs include Fruquintinib (HMPL-013) for the treatment of colorectal cancer, gastric cancer, and various other solid tumors; Savolitinib (AZD6094, HMPL-504) for monotherapy and in combination with immunotherapy and targeted therapy; Sovleplenib (HMPL-523) for various hematological cancers such as indolent non-Hodgkin's lymphomas and certain chronic immune diseases in the U.S., Europe, China and Australia; and Amdizalisib (HMPL-689) for various subtypes of advanced relapsed or refractory non-Hodgkin's lymphoma, including follicular lymphoma and marginal zone lymphoma; among others.